FibroScan® by echosens
gold standard solution for comprehensive management of liver health
Current NASH drug developments focus on patients with NASH at-risk of progression to cirrhosis or with compensated cirrhosis defined by Active Fibrotic NASH (NASH + NAS≥4 + F≥2).
Fast™ combines FibroScan® examination results (LSM by VCTE™ & CAP™) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-NASH, at the point-of-care, reducing invasive and costly procedures.
Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Improvements in Fast™ are consistent with amelioration of key histologic features of NASH, including both inflammation and fibrosis.
Fast™ score demonstrated good discrimination for fibrotic NASH in our cohort.
I believe that Fast™ is a key element for NASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.
Fast™ calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Fast™ is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.